Results 1 to 7 of 7
Page 1 of 1
TypeTitleAuthor(s)YearViews
miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma
Journal:
PLoS One
Publisher:
Public Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
Liu, ML; Xu, Z; Shek, HP; Wong, KF; Lee, NPY; Poon, RTP; Chen, J; Luk, JMC201437
 
Oncofetal Molecules as Biomarkers and Drug Targets for Hepatic Cancer
Book:
New Advances on Disease Biomarkers and Molecular Targets in Biomedicine
Publisher:
Humana Press
Shek, HP; Lai, TCW; Fatima, S; Lee, NPY201331
 
Implications of the use of eukaryotic translation initiation factor 5A (eIF5A) for prognosis and treatment of hepatocellular carcinoma
Journal:
International Journal of Hepatology
Shek, HP; Fatima, S; Lee, NPY201265
 
Tumorigenic properties of serine peptidase inhibitor, Kazal type 1 (SPINK1) in hepatocellular carcinoma (Abstract)
Proceedings/Conference:
18th Hong Kong International Cancer Congress, 3-5 November 2011, Hong Kong.
Shek, HP; Lee, NPY201164
 
Targeting serine peptidase inhibitor, Kazal type 1 (SPINK1) as a potential treatment for hepatocellular carcinoma (Abstract)
Proceedings/Conference:
International Liver Cancer Association Fifth Annual Conference, 2-4 September 2011, Hong Kong.
Shek, HP; Luk, JMC; Lee, NPY2011100
 
Tumorigenic properties of serine peptidase inhibitor, Kazal type 1 (SPINK1) in hepatocellular carcinoma (Poster & Abstract)
Proceedings/Conference:
The 18th Hong Kong International Cancer Congress, Hong Kong, 3-5 November 2011
Shek, HP; Lee, NPY201157
 
The role of serine peptidase inhibitor, Kazal type I (SPINK1) in hepatocellular carcinoma (Poster Presentation)Shek, HP; Luk, JMC; Kwong, A; Lee, NPY201093
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download